Cargando…

Musings on genome medicine: Hepatitis C

Hepatitis C is a viral disease transmitted principally by blood, which affects millions of people worldwide. A significant proportion of those affected develop severe liver disease as a result. Only a fraction of patients are responsive to interferon treatment, highlighting the need for further rese...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, David G, Orkin, Stuart H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829929/
https://www.ncbi.nlm.nih.gov/pubmed/20193049
http://dx.doi.org/10.1186/gm125
_version_ 1782178130793857024
author Nathan, David G
Orkin, Stuart H
author_facet Nathan, David G
Orkin, Stuart H
author_sort Nathan, David G
collection PubMed
description Hepatitis C is a viral disease transmitted principally by blood, which affects millions of people worldwide. A significant proportion of those affected develop severe liver disease as a result. Only a fraction of patients are responsive to interferon treatment, highlighting the need for further research into genetic factors involved in response to therapy in order to optimize treatment. The only current approach for end-stage disease is liver transplant, which ironically does not cure the condition, and thus poses a clinical dilemma in the face of liver-donor shortage.
format Text
id pubmed-2829929
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28299292011-01-27 Musings on genome medicine: Hepatitis C Nathan, David G Orkin, Stuart H Genome Med Musings Hepatitis C is a viral disease transmitted principally by blood, which affects millions of people worldwide. A significant proportion of those affected develop severe liver disease as a result. Only a fraction of patients are responsive to interferon treatment, highlighting the need for further research into genetic factors involved in response to therapy in order to optimize treatment. The only current approach for end-stage disease is liver transplant, which ironically does not cure the condition, and thus poses a clinical dilemma in the face of liver-donor shortage. BioMed Central 2010-01-27 /pmc/articles/PMC2829929/ /pubmed/20193049 http://dx.doi.org/10.1186/gm125 Text en Copyright ©2010 BioMed Central Ltd
spellingShingle Musings
Nathan, David G
Orkin, Stuart H
Musings on genome medicine: Hepatitis C
title Musings on genome medicine: Hepatitis C
title_full Musings on genome medicine: Hepatitis C
title_fullStr Musings on genome medicine: Hepatitis C
title_full_unstemmed Musings on genome medicine: Hepatitis C
title_short Musings on genome medicine: Hepatitis C
title_sort musings on genome medicine: hepatitis c
topic Musings
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829929/
https://www.ncbi.nlm.nih.gov/pubmed/20193049
http://dx.doi.org/10.1186/gm125
work_keys_str_mv AT nathandavidg musingsongenomemedicinehepatitisc
AT orkinstuarth musingsongenomemedicinehepatitisc